QUOTED. 16 April 2020. Joe Brennan.
US regulators are allowing Dexcom and Abbott to bring their continuous glucose monitoring devices directly to hospitals for remote monitoring of COVID-19 patients. Here’s why telehealth consultant Joe Brennan, Moonshot Health Consulting, thinks this could open a new market opportunity post-pandemic.
“One, it allows [CGM] to be used within the four walls of the hospital. Two, when that patient is discharged, they already know how to use the device, they’re already comfortable with it. There is that continuity of care even after they are discharged from the hospital. It has potential to create a whole new market.”- Joe Brennan, telehealth consultant, Moonshot Health Consulting
Click here for a free trial of Medtech Insight